Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Phacilitate, a leading brand that connects advanced therapies industry leaders through inspiring conferences, vibrant communities and market intelligence, today presented Katherine A. High, M.D. with ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns. The post 2 cheap shares that could be takeover targets in 2025 ...